Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.
Daniel Carrizosa, MD, MS
Advertisement
Articles by Daniel Carrizosa, MD, MS
Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.
Advertisement
Latest Updated Articles
Dr. Carrizosa on the Efficacy Findings of the CRESTONE Trial in NRG1 Fusion–Positive Solid TumorsPublished: June 20th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5